<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SHIMANE BREAST CANCER STUDY GROUP, JAPAN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative Effects of the Administration Period of Adjuvant Chemotherapy using Doxifluridine (5'-DFUR) for 1 Year &lt;em&gt;Versus&lt;/em&gt; 3 Years after Breast Cancer Surgery by the Shimane Breast Cancer Study Group</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">591-597</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><issue><style face="normal" font="default" size="100%">1B</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The present study investigated the efficacy of oral doxifluridine (5'-DFUR) by comparing the survival between patients who received 5'-DFUR at 800 mg/body daily for 1 or 3 years after surgery for stage 1, 2 or 3 breast cancer. Patients and Methods: Ninety-two patients were enrolled from January 1995 to December 1997, of whom 87 were eligible. The patients were stratified into pre-menopausal and post-menopausal groups, and then each group was further stratified into 1-year or 3-year administration groups. All patients were given endocrine therapy, with gosereline acetate (3.6 mg/body, monthly) for the pre-menopausal patients and tamoxifen (20 mg/day, daily) for the post-menopausal patients for 3 years. Results: The median follow-up duration was 9.5 years. Although no differences were found in the overall or disease-free survivals between the administration groups, subset analysis demonstrated that, in the pre-menopausal patients, the 3-year administration group showed a significantly higher overall survival rate than the 1-year administration group, but not in post-menopausal patients. A multivariate analysis also indicated that the administration duration of 5'-DFUR was a significant factor for disease-free survival. Conclusion: The present study supports the usefulness of 5'-DFUR for adjuvant chemotherapy against breast cancer, especially for pre-menopausal patients; however, further clinical study with a much larger sample size is necessary to reach a conclusive result. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>